A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.
Eskandarain ShafuddinGraham D MillsMark D HolmesPhillippa J PoolePeter R MullinsPeter N BlackPublished in: Journal of negative results in biomedicine (2015)
Twelve-weeks of prophylaxis with roxithromycin/doxycycline combination or roxithromycin alone did not reduce COPD exacerbations in patients with history of frequent exacerbations. These findings do not support the use of these antibiotics to prevent exacerbations in COPD patients.
Keyphrases
- chronic obstructive pulmonary disease
- cystic fibrosis
- lung function
- double blind
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- prognostic factors
- open label
- randomized controlled trial
- peritoneal dialysis
- placebo controlled
- gestational age
- study protocol
- air pollution
- patient reported outcomes